Research advances in fecal microbiota transplantation for the treatment of HBeAg-positive chronic hepatitis B / 临床肝胆病杂志
Journal of Clinical Hepatology
;
(12): 414-416, 170.
Article
in Chinese
| WPRIM
| ID: wpr-788408
ABSTRACT
HBeAg seroconversion is an important process during antiviral therapy for patients with HBeAg-positive chronic hepatitis B (CHB), while the first-line antiviral drugs, such as entecavir and tenofovir disoproxil fumarate, tend to have low HBeAg clearance rate and/or seroconversion rate, and at present, there is still a lack of effective radical treatment regimens. Latest studies have shown that fecal microbial transplantation (FMT) can induce HBeAg clearance in HBeAg-positive CHB patients receiving long-term antiviral therapy. This article reviews the research advances in the role of FMT in inducing HBeAg clearance in HBeAg-positive CHB patients and points out that FMT may become a new treatment regimen for HBeAg-positive CHB patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Clinical Hepatology
Type:
Article
Similar
MEDLINE
...
LILACS
LIS